<DOC>
	<DOCNO>NCT02504944</DOCNO>
	<brief_summary>The aim present study evaluate safety efficacy propranolol 0.2 % eye drop treat preterm newborn precocious stage retinopathy prematurity ( ROP ) . Preterm newborn ( gestational age 23-32 week ) stage 1 ROP receive propranolol 0.2 % eye drop treatment retinal vascularization complete , 90 day . Propranolol concentration measure dried blood spot steady state ( 10th day ) . Cardiovascular respiratory parameter continuously monitor . Blood sampling check metabolic , renal liver function perform periodically , well cardiac function , order verify treatment safety . Serial ophthalmological evaluation plan monitor efficacy treatment , ROP progression possible complication .</brief_summary>
	<brief_title>Safety Efficacy Propranolol 0.2 % Eye Drops Treating Retinopathy Premature : A Pilot Study ( DROP-ROP-0.2 % )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Preterm newborn ( gestational age 2332 week ) stage 1 ROP A sign parental inform consent Newborns heart failure Newborns recurrent bradycardia ( heart rate &lt; 90 beat per minute ) Newborns second third degree atrioventricular block Newborns congenital cardiovascular anomaly , except persistent ductus arteriosus , patent foramen ovale small ventricular septal defect Newborns hypotension Newborns renal failure Newborns actual cerebral haemorrhage Newborns diseases contraindicate use betaadrenoreceptor blocker . Newborns severe stage ROP stage 1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Retinopathy prematurity</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Newborn</keyword>
	<keyword>Eye Drops</keyword>
	<keyword>Retinal angiogenesis</keyword>
	<keyword>Retinal neovascularization</keyword>
</DOC>